Bank of Japan Eyes April Rate Hike Despite Inflation Dip, ING Says 
U.S. Oil Prices Slide as Middle East Ceasefire Talks Spark Market Optimism 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Asian Stocks Gain Amid Iran Conflict Uncertainty 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Oil Prices Plunge Over 6% as Middle East Ceasefire Hopes Ease Supply Fears 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
